Professional development Vacancies

Regarding amendments to the package inserts of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, amitriptylinoxide

14.01.2025 1124 views

In accordance with paragraph 8 of Section IV of the Procedure for Expert Evaluation, the applicant must amend the instructions for medical use of the medicinal product upon receipt of new data, including bringing the instructions for medical use into line with the approved instructions for medical use of the original (reference) medicinal product, and ensure that the information on the medicinal product corresponds to current scientific knowledge.

The Pharmacovigilance Risk Assessment Committee (PRAC), based on the analysis of Periodic Safety Update Reports (PSURs) for medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, amitriptylinoxide, PSUSA/00010374/202401, made the following conclusions.

In view of the available data on drug-induced eosinophilia with systemic symptoms (DRESS) from the literature and spontaneous reports, including in some cases a close temporal relationship, a case with a positive de-challenge test and/or a case with a positive re-challenge test, as well as in view of a plausible mechanism of action, the PRAC considers that a causal relationship between the above-mentioned events and the use of amitriptyline is at least reasonably possible. Thus, the PRAC concluded that the instructions for medical use of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, amitriptylinoxide should be amended accordingly.

Having considered the PRAC recommendations, the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) agrees with the overall conclusions of the PRAC and the grounds for the recommendations.

Based on the scientific conclusions regarding amitriptyline, amitriptyline/amitriptylinoxide, and amitriptylinoxide, the CMDh considers that the benefit/risk balance of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, or amitriptylinoxide remains unchanged, subject to the proposed changes being made to the instructions for medical use.

Changes to be made to the relevant sections of the package inserts (new text underlined and in bold).

  • “Special precautions for use” section

…..

Severe skin reactions

Severe cutaneous adverse reactions (SCARs), including drug-induced eosinophilia with systemic symptoms (DRESS), which can be life-threatening or fatal, have been reported with the use of amitriptyline. Most of these reactions occurred within 2-6 weeks.

When prescribing the medicinal product, patients should be informed about the signs and symptoms and closely monitored for skin reactions.

If signs and symptoms suggesting these reactions appear, <name of the medicinal product> should be discontinued immediately, treatment with <name of the medicinal product> must in no case be resumed in this patient, and alternative treatment should be considered (if necessary).

  • “Adverse reactions” section

The following adverse reactions should be added to the subsection “Skin and subcutaneous tissue disorders” with the frequency “unknown”.

Summary of the safety profile:

Severe cutaneous adverse reactions (SCARs), including drug-induced eosinophilia with systemic symptoms (DRESS), have been reported with the use of amitriptyline (see section “Special warnings and precautions for use”).

Table of adverse reactions

Subsection “Skin and subcutaneous tissue disorders” with the frequency “not known”

Drug-induced eosinophilia with systemic symptoms (DRESS)

Changes to the safety information for medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, and amitriptylinoxide based on the results of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 02 – 05 September 2024

The European Medicines Agency (EMA) has published the minutes of the meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) of 02 – 05 September 2024. Following the meeting, a decision was made on the need to introduce safety-related changes to the registration materials/instructions for medical use of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, amitriptylinoxide.

Amitriptyline, amitriptyline/amitriptylinoxide, amitriptylinoxide – PSUSA/00010374/202401

Amitriptyline is a tricyclic antidepressant indicated in adults for the treatment of major depressive disorder, neuropathic pain, prophylaxis of chronic tension-type headache, and prophylaxis of migraine, and also for the treatment of nocturnal enuresis in children aged 6 years and older, provided that there is no organic pathology, including spina bifida and associated conditions, and in the absence of response to non-pharmacological and pharmacological treatment, in particular with antispasmodics and medicinal products containing vasopressin.

Based on the assessment of Periodic Safety Update Reports (PSURs), the PRAC reviewed the benefit/risk balance of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, and amitriptylinoxide, and made the following recommendations.

Summary of recommendations and conclusions

  • Based on the analysis of safety and efficacy data, the benefit/risk ratio of medicinal products containing amitriptyline, amitriptyline/amitriptylinoxide, and amitriptylinoxide remains unchanged for the approved indications.
  • Nevertheless, the instructions for medical use must be updated by adding a warning about drug-induced eosinophilia with systemic symptoms (DRESS), and also by adding it as an adverse reaction with the frequency "unknown." Thus, the existing provisions of the instructions for medical use must be amended1.

In the next periodic safety update report (PSUR), registration certificate holders should provide a cumulative review of oral mucosal depigmentation and fall-related injuries associated with the use of antidepressants, and should also carefully monitor and report aggregate information on cases of disorientation and atrial fibrillation after amitriptyline overdose, gestational diabetes, Brugada syndrome (unmasking), treatment of overdose with lipid emulsions, dementia, and on the use of antidepressants during pregnancy.

____________________________________________________________________________

1Update of the sections “Special warnings and precautions for use” and “Adverse reactions” of the instructions for medical use. The risk assessment report and the PRAC recommendation are forwarded to the CMDh for decision.

List of medicinal products containing amitriptyline and authorized for medical use in Ukraine (according to the State Register of Medicinal Products as of 21.11.2024).

TO ANALYZE THE PUBLISHED INFORMATION AND SUBMIT THE CORRESPONDING APPLICATION FOR AMENDMENTS TO THE REGISTRATION MATERIALS, THE APPLICANT MUST USE THE ORIGINAL TEXT POSTED AT THE LINKS:

LINK LINK LINK LINK